Want to see CMND full AI Analyst Report?
Top Page
Clearmind Medicine
(NASDAQ:CMND)
Select Model
Select Model
Rating:43Neutral
Price Target:
$1.50
Action:N/A
Date:10/19/26
The score is driven primarily by weak financial performance: no revenue, ongoing losses, and material cash burn increase financing risk despite improved leverage and equity. With no usable technical indicators and limited valuation usefulness due to negative earnings and no dividend data, there are few offsetting positives in the provided dataset.
Positive Factors
Improved capitalization and lower leverage
Improved equity and much lower leverage provide a stronger financial base for advancing programs over the next several months. This reduces balance-sheet pressure and may preserve strategic flexibility, although it does not eliminate the need to fund ongoing losses.
Negative Factors
No commercial revenue
Zero revenue across annual periods and TTM confirms the business has not yet reached commercial scale. Persistent operating losses mean current activities rely on continued funding rather than internally generated sales, leaving profitability dependent on successful development and eventual commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved capitalization and lower leverage
Improved equity and much lower leverage provide a stronger financial base for advancing programs over the next several months. This reduces balance-sheet pressure and may preserve strategic flexibility, although it does not eliminate the need to fund ongoing losses.
Read all positive factors
Clearmind Medicine (CMND) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.01M
Dividend YieldN/A
Average Volume (3M)30.69K
Price to Earnings (P/E)―
Beta (1Y)1.15
Revenue GrowthN/A
EPS Growth74.01%
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-89.20
Shares Outstanding507,404
10 Day Avg. Volume26,042
30 Day Avg. Volume30,693
Financial Highlights & Ratios
PEG Ratio1.90
Price to Book (P/B)339.13
Price to Sales (P/S)0.00
P/FCF Ratio-85.43
Enterprise Value/Market Cap-3.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit211.10
Enterprise Value/Ebitda1.39
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Clearmind Medicine Business Overview & Revenue Model
Company Description
Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently ...
Clearmind Medicine Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
20
Very Negative
| Breakdown | TTM | Oct 2025 | Oct 2024 | Oct 2023 | Jan 2023 | Jan 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -54.27K | -49.36K | -51.07K | -57.43K | -119.62K | -2.53K |
| EBITDA | -8.23M | -3.72M | -4.79M | -8.53M | -9.75M | ― |
| Net Income | -7.49M | -3.86M | -5.25M | -8.61M | -9.93M | -3.66M |
Balance Sheet | ||||||
| Total Assets | 16.91M | 6.08M | 10.10M | 5.95M | 1.12M | 4.16M |
| Cash, Cash Equivalents and Short-Term Investments | 15.93M | 5.58M | 9.55M | 5.51M | 437.77K | 3.71M |
| Total Debt | 1.80M | 1.78M | 73.97K | 0.00 | 52.11K | 0.00 |
| Total Liabilities | 3.96M | 4.89M | 5.77M | 4.97M | 2.62M | 288.19K |
| Stockholders Equity | 12.95M | 1.19M | 4.33M | 983.47K | -1.50M | 3.87M |
Cash Flow | ||||||
| Free Cash Flow | -7.54M | -4.73M | -6.76M | -6.30M | -5.06M | -2.25M |
| Operating Cash Flow | -7.54M | -4.73M | -6.76M | -6.30M | -5.06M | -2.08M |
| Investing Cash Flow | -2.15M | -541.97K | -331.43K | -26.23K | -7.55K | -184.03K |
| Financing Cash Flow | 18.34M | 2.62M | 8.71M | 11.66M | 694.52K | 5.39M |
Clearmind Medicine Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $18.34M | -0.48 | -77.03% | ― | ― | ― | |
44 Neutral | $6.45M | -0.09 | -168.05% | ― | ― | 87.05% | |
43 Neutral | $3.01M | -0.07 | -87.29% | ― | ― | 74.01% | |
41 Neutral | $10.79M | -0.25 | -1693.21% | ― | ― | 45.78% |
* Healthcare Sector Average
CMND
Clearmind Medicine
5.94
-3,137.42
-99.81%
ENVB
Enveric Biosciences
1.51
-5.84
-79.45%
ADIL
Adial Pharmaceuticals
4.11
-4.86
-54.19%
SILO
Silo Pharma
1.20
-7.17
-85.66%
PBM
Psyence Biomedical
4.52
-16.32
-78.31%
NEUP
Neuphoria Therapeutics
3.48
-0.57
-14.07%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.